Merck & Co., Inc. is getting into the well-trodden space of bispecific antibodies by acquiring CN201, a CD19xCD3-directed candidate, from a Chinese biotech company.
Merck Steps Into CD19 Bispecific Antibody Ring With Curon Deal
The drug maker is spending up to $1.3bn to acquire rights to CN201, a CD19xCD3-directed bispecific antibody that it plans to develop for B-cell malignancies and autoimmune diseases.
